- Home
- SPGI vs BMY Comparison
SPGI vs BMY Comparison
Compare SPGI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPGI | BMY |
|---|---|---|
| Founded | 1860 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6B | 113.5B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SPGI | BMY |
|---|---|---|
| Price | $403.03 | $59.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 28 |
| Target Price | ★ $518.52 | $66.17 |
| AVG Volume (30 Days) | 1.6M | ★ 10.0M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | 0.98% | ★ 4.22% |
| EPS Growth | 18.70 | ★ 178.46 |
| EPS | ★ 4.69 | 2.93 |
| Revenue | $6,063,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | N/A | $3.41 |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $84.27 | ★ $20.43 |
| Revenue Growth | ★ 7.10 | N/A |
| 52 Week Low | $381.61 | $42.52 |
| 52 Week High | $552.25 | $68.64 |
Technical Indicators
Market Signals| Indicator | SPGI | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 36.70 |
| Support Level | $381.61 | $56.46 |
| Resistance Level | $453.40 | $60.10 |
| Average True Range (ATR) | 7.65 | 1.29 |
| MACD | 0.26 | -0.33 |
| Stochastic Oscillator | 67.54 | 27.41 |
Price Performance
Historical ComparisonAbout SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include energy (formerly commodity insights, this segment includes Platts and other data) and indexes. S&P spun off Mobility Global (Carfax and other auto data) on July 1, 2026.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.